bullish

Encouraging NS-065 Top-Line Data, However, Uptravi’s Global Ramp-Up Remains the Key

141 Views29 Jun 2018 20:21
We reiterate our “Overweight” rating on the stock after reviewing our model post FY17 (YE Mar-18) earnings. Our rating is subject to Uptravi’s...
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Dion Stéfan Büchner M.D., FCAP
Asia Healthcare Analyst
Pathology Associates Limited
Japan & ChinaHealth CareEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
x